▎This article is contributed by Ying’en Biotech (slightly edited) Since the first antibody-drug conjugate (ADC) was approved for the treatment of acute myeloid leukemia in 2000, after more than twenty years of exploration and development, 14 ADC drugs have been successfully approved for clinical treatment of tumors. In August 2022, the FDA announced the accelerated … Read more
Introduction Antibody-drug conjugates (ADC) are comprised of monoclonal antibodies that target specific antigens linked to small molecule cytotoxic drugs via a linker, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (trade name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more
Last week, while introducing the “Breakthroughs and Innovations in Lung Cancer Treatment” from the “AACR 2021 Annual Report on Anti-Cancer Progress”（>> Click to review）, I mentioned a popular research topic—Antibody-Drug Conjugates (ADCs), which saw two new ADCs approved and two ADCs expanding their indications in 2021. Some readers expressed a desire to learn more about … Read more
The development of ADC drugs has not been smooth sailing, with nearly 100 years of history since the concept of the “magic bullet” was proposed, but ultimately, the clouds have parted to reveal the moon. DS8201 has redefined ADC, but it is not the end of ADC drugs, rather a new beginning. A comprehensive understanding … Read more
ADC Field Blooms, new technologies evolve like a rolling tide, propelling biomedicine into high-speed mode. This is the best of times. As early as the early 20th century, Paul Ehrlich first proposed the concept of “magic bullets”; however, the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), was not approved until nearly a century later. Every cloud … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the drug payload … Read more
Introduction Antibody-drug conjugates (ADC) combine the high specificity of monoclonal antibodies with the high potency of small molecule cytotoxic drugs to enhance the targeting of cancer therapies and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs can release highly active cytotoxins within tumor tissues, theoretically leading to higher efficacy. ADCs have undergone … Read more
Key Content Preview:In recent years, antibody-drug conjugates (ADCs) have developed rapidly. As of August 2023, there are a total of 15 ADCs on the market globally, with over 1200 drugs under research. In June this year, Nature Biotechnology published a brief report titled “ADCs’ Revival”, highlighting the “breakthrough momentum” of ADCs in new drug development. … Read more
Antibody-drug conjugates (ADC), also known as “magic bullets,” use monoclonal antibodies (Antibody) to deliver small molecule drugs (Drug) directly to tumor cells expressing specific antigens through a linker (Conjugate). In recent years, ADC drugs have rewritten the treatment guidelines for blood cancers, breast cancer, ovarian cancer, and lung cancer, providing patients with significantly improved clinical … Read more
In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that drugs could be developed to specifically target pathogens without affecting normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target specificity of monoclonal antibodies with the anti-tumor properties of cytotoxic molecules. After decades … Read more